目前尚不清楚中国父母对疫苗的偏好是什么,这些疫苗可能会被添加到未来的免疫计划中。这项研究的目的是评估中国父母对疫苗属性的偏好。我们在上海免疫诊所调查了年龄≤3个月的幼儿的父母,中国,在2017年。我们使用离散选择实验(DCE)向父母提供两个假设的疫苗概况之间的选择,这些疫苗使用以下属性进行描述:成本,副作用的风险,疫苗制造商的位置,疫苗测试,疫苗有效性,疾病的严重程度,疾病患病率。偏好效用的逻辑回归输出估计。总的来说,599名护理人员完成了DCE。父母表示对疫苗的偏好较低,其中30%的机会发烧为不良事件,而10%的机会(OR:0.53,95%CI:0.44,0.64),对于疫苗,只有85%有效vs95%有效(OR:0.55,95%CI:0.48,0.62),与国产疫苗相比,进口疫苗(OR:0.74,95%CI:0.60,0.92)和未在中国儿童中进行测试的疫苗(OR:0.45,95%CI:0.37,0.53)。较富裕的群体更喜欢更昂贵的疫苗,而较不富裕的群体则没有表达基于成本的偏好。在中国推广疫苗应侧重于父母陈述的偏好,其中包括过去在中国儿童中进行的测试-也就是说,事实上,中国所有许可疫苗的要求。关于这些试验的信息可以强调不良事件的低风险和高有效性。
It is not clear what kind of preferences parents in China would have for vaccines that could be added to a future immunization schedule. This study\'s aim was to assess Chinese parents\' preferences for attributes of vaccines. We surveyed parents of young infants ≤3 months of age at immunization clinics in Shanghai, China, in 2017. We used a discrete choice experiment (DCE) to present parents with choices between two hypothetical profiles of vaccines which were described using the following attributes: cost, risk of side effect, location of vaccine manufacturer, vaccine testing, vaccine effectiveness, severity of disease, disease prevalence. A logistic regression output estimates of preference utilities. In total, 599 caregivers completed the DCE. Parents expressed lower preference for vaccines with a 30% chance of fever as an adverse event vs a 10% chance (OR: 0.53, 95% CI: 0.44, 0.64), for vaccines only 85% effective vs those 95% effective (OR: 0.55, 95% CI: 0.48, 0.62), and for imported vaccines (OR: 0.74, 95% CI: 0.60, 0.92) and those not tested in Chinese children (OR: 0.45, 95% CI: 0.37, 0.53) compared to domestic vaccines. More affluent groups preferred more expensive vaccines whereas less affluent groups did not express cost-based preferences. Promotion of vaccines in China should focus on parents\' stated preferences, which include past testing done in Chinese children - which is, in fact, required of all licensed vaccines in China. Information about these trials could emphasize low risk of adverse events and high effectiveness.